Genentech pens $1.27B deal to access Alector's preclinical blood-brain barrier asset
Genentech has signed a deal worth up to $1.27 billion to license a preclinical blood-brain barrier asset from Alector, adding to its neurology pipeline.
Alector
Alector is a clinical-stage biotechnology company developing immuno-neurology therapies for neurodegenerative diseases. Its lead programs target progranulin (PGRN) and TREM2 pathways, with a major 2026 setback when partner GSK walked away from its $700M upfront Alzheimer's collaboration after consecutive clinical failures.
Company Info
Sector:Biotechnology / Neurodegeneration
Headquarters:South San Francisco, California, USA
Founded:2013
Website:www.alector.com/
Recent News
GSK abandons Alector after back-to-back neuro stumbles
GSK abandons Alector after back-to-back neuro stumbles (BioSpace.)
GSK cuts losses on $700M upfront Alzheimer’s collab with Alector
GSK cuts losses on $700M upfront Alzheimer’s collab with Alector (Fierce Biotech.)
GSK ends brain drug alliance with Alector
BioPharma Dive reports: GSK ends brain drug alliance with Alector.